

PHARMING

PHARMING CONCLUDES SECOND CALL OF €10 MILLION EQUITY WORKING CAPITAL FACILITY

Leiden, The Netherlands, September 26, 2012. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today announces that the second call under the Equity Working Capital facility is now concluded and that, including an additional 15,640,000 shares that were issued between the last update on this second call, as announced on September 21, 2012 and today, a total of 80,736,000 shares were sold to the investors for total cash proceeds of approximately €1,121,000. Including the €1,203,000 proceeds following the first call concluded on August 31, 2012, a total of €2,324,000 has now been raised in relation to the €10.0 million equity working capital facility and accordingly this leaves €7,676,000 available for additional financing through this instrument if and when needed.

The number of outstanding shares as per today is 888,553,129.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. Ruconest® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). Ruconest® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. A feasibility study, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A is underway with partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com. To download the Pharming Group Investor Relations App, click [here](#).

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400

FTI Consulting

Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

###